Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

Published:2020-01-15 Issue:8 Volume:63 Page:3868-3880
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chianelli Donatella¹,Rucker Paul V.¹,Roland Jason¹,Tully David C.¹²^ORCID,Nelson John¹,Liu Xiaodong¹,Bursulaya Badry¹,Hernandez Eloy D.¹,Wu Jane¹,Prashad Mahavir³,Schlama Thierry⁴,Liu Yugang³,Chu Alan¹,Schmeits James¹,Huang David J.¹,Hill Robert¹,Bao Dingjiu¹,Zoll Jocelyn¹,Kim Young¹,Groessl Todd¹,McNamara Peter¹,Liu Bo¹,Richmond Wendy¹,Sancho-Martinez Ignacio¹,Phimister Andrew²,Seidel H. Martin¹,Badman Michael K.⁵,Joseph Sean B.¹,Laffitte Bryan¹,Molteni Valentina¹^ORCID

Affiliation:

1. Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California 92121, United States

2. Novartis Institutes for Biomedical Research, Emeryville, California 94608, United States

3. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, United States

4. Novartis Pharma AG, Basel 4002, Switzerland

5. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01621

Reference47 articles.

1. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies

2. The global NAFLD epidemic

3. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

4. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

5. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

2. Construction of Diverse Fused Chromene Frameworks via Isocyanide-Based Three-Component Reaction;The Journal of Organic Chemistry;2024-07-12

3. Immunology of bile acids regulated receptors;Progress in Lipid Research;2024-07

4. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders;Saudi Journal of Gastroenterology;2024-05-06

5. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets;Signal Transduction and Targeted Therapy;2024-04-26